Review: Rheumatoid Arthritis–Associated Interstitial Lung Disease Save

RA-ILD represents the most severe extra-articular manifestation of rheumatoid arthritis, affecting an estimated 1% of the adult population in the US and Northern Europe. Prevalence estimates vary widely  (up to 58%), reflecting different diagnostic criteria, imaging modalities, and study populations. Clinically detected RA-ILD likely affects 5–10% of RA patients, while subclinical HRCT findings are far more common, especially at autopsy (~ two-thirds).

RA-ILD is a leading cause of RA-related mortality, with median post-diagnosis survival of only 3–7 years.

Two dominant mechanistic hypotheses have emerged:

• Joint-to-lung hypothesis: Immune responses against citrullinated peptides in joints cross-react with pulmonary antigens. Notably, anti-CCP antibodies and RF are detectable years before ILD onset, and lung disease can precede arthritis.
• Lung-first hypothesis: The lung itself is an initial site of protein citrullination — potentially triggered by smoking or microbial exposure — which then drives systemic autoimmunity.

Key genetic risk factors include the MUC5B promoter variant (rs35705950), which is associated with UIP pattern and worse survival, and shortened telomere length, both of which overlap with idiopathic pulmonary fibrosis (IPF) susceptibility loci. Male sex, older age at RA onset, seropositivity (RF+, anti-CCP+), and smoking are well-established clinical risk factors.

Diagnosis requires a multidisciplinary team (MDT) approach involving rheumatology, pulmonology, radiology, and pathology. HRCT is the cornerstone of evaluation.

Dominant HRCT patterns in RA-ILD:

• Usual Interstitial Pneumonia (UIP): Most common pattern; carries the worst prognosis with a fibrotic, honeycombing phenotype analogous to IPF.
• Nonspecific Interstitial Pneumonia (NSIP): More prevalent in seropositive women; better prognosis than UIP.
• Other patterns: Organizing pneumonia (OP), desquamative interstitial pneumonia (DIP), lymphoid interstitial pneumonia (LIP), and diffuse alveolar damage (DAD) occur less frequently.

Mimics of RA-ILD should be considered: hypersensitivity pneumonitis, drug-induced ILD (including MTX pneumonitis), infection, and other CTD-ILD. Bronchoalveolar lavage and, rarely, surgical lung biopsy may be required in diagnostically ambiguous cases.

The primary goal is optimal systemic RA control — the most effective intervention for limiting ILD progression. Subsequent decisions depend on ILD pattern, trajectory, and severity.

Methotrexate — Reconsidering the Contraindication:

Historically, MTX was implicated in causing or worsening ILD. Current evidence contradicts this: MTX does not appear to increase RA-ILD risk, and some data suggest a potentially protective effect (lower ILD incidence). MTX pneumonitis is rare, distinct from RA-ILD, and usually reversible. Continuing or initiating MTX in RA-ILD patients with active synovitis should be considered on an individualized basis rather than reflexively avoided.

Immunosuppressive Agents with Emerging Evidence:

• Mycophenolate mofetil (MMF): Widely used first-line agent for ILD; stabilizes pulmonary function in observational studies.
• Rituximab (RTX): Preferred bDMARD for progressive RA-ILD, particularly in UIP and in patients with high autoantibody titers. TNF inhibitors should generally be avoided given risk of ILD exacerbation.
• Abatacept: Shows promise, with a favorable pulmonary safety profile and potential benefit in UIP-pattern disease.
• JAK inhibitors: Conflicting signals — potential benefit in inflammation-driven ILD, but pulmonary safety data remain limited; use with caution.

Antifibrotic Therapy:

• Nintedanib: The only agent with RCT evidence in RA-ILD (INBUILD trial subgroup). Slows FVC decline in progressive fibrosing ILD. Now a guideline-endorsed option for progressive pulmonary fibrosis (PPF) in RA-ILD.
• Pirfenidone: Phase 2 RCT (Solomon et al., 2023) demonstrated safety and tolerability in RA-ILD; efficacy data are preliminary.

Adverse prognostic factors include UIP pattern, male sex, lower baseline FVC/DLCO, older age, and MUC5B variant carriage. Acute exacerbations — often triggered by infection, aspiration, or drug toxicity — carry extremely high mortality.

Monitoring should include serial PFTs (every 6–12 months), HRCT at baseline and when clinically indicated, and 6-minute walk tests in advanced disease. Multidisciplinary reassessment is recommended at each decision point.

KEY TAKEAWAYS

• RA-ILD carries a median survival of 3–7 years post-diagnosis and is the leading driver of RA-related mortality — early detection is paramount.
• UIP is the dominant HRCT pattern and confers the worst prognosis; MDT evaluation is essential to distinguish RA-ILD from IPF, HP, and drug toxicity.
• MTX does not increase RA-ILD risk and should not be reflexively withheld — its cessation may deprive patients of effective RA control without pulmonary benefit.
• Rituximab and abatacept are preferred bDMARDs in RA-ILD; TNF inhibitors carry ILD exacerbation risk and should generally be avoided.
• Nintedanib (antifibrotic) is guideline-endorsed for progressive fibrosing RA-ILD; pirfenidone shows early promise but awaits Phase 3 confirmation.
• Optimizing systemic RA disease control remains the cornerstone of RA-ILD management — joint and lung disease must be treated in tandem.